FREQUENTLY ASKED QUESTIONS

What is the indication for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in adults?

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older.

What are the contraindications for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in adults?

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

What are the warnings and precautions for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in adults?

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

What are the most common adverse reactions for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in adults?

The most commonly reported solicited adverse reactions in individuals 18 through 49 years of age were: injection-site pain (75.8%), fatigue (34.3%), myalgia (28.8%), headache (26.5%), injection-site swelling (21.7%), injection-site erythema (15.1%) and arthralgia (12.7%).

The most commonly reported solicited adverse reactions in individuals 50 years of age and older were: injection-site pain (66.8%), myalgia (26.9%), fatigue (21.5%), headache (18.9%), injection-site swelling (15.4%), injection-site erythema (10.9%) and arthralgia (7.7%).

What is the recommended dosage and administration of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for adults?

For intramuscular use only.

Administer a single 0.5 mL dose.

Hold the prefilled syringe horizontally and shake vigorously immediately prior to use to obtain an opalescent suspension in the prefilled syringe.

Do not use the vaccine if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if particulate matter or discoloration is observed.

Can VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) be administered concurrently with influenza vaccine in adults?

VAXNEUVANCE may be given at the same time as seasonal inactivated influenza vaccine.

What pneumococcal serotypes are contained in VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)?

VAXNEUVANCE is a sterile suspension of purified capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F.

When was VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) first approved for use by the FDA?

VAXNEUVANCE was first approved by the FDA in 2021.

How do I report a suspected adverse event?

To report a suspected adverse reaction, contact Merck at 1-877-888-4231 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

How do I report a suspected product quality complaint?

To report a suspected product quality complaint, contact Merck at 1-877-888-4231.

What are the storage requirements for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)?

Store refrigerated at 2°C to 8°C (36°F to 46°F).

Do not freeze. Protect from light.

What is the CPT Code for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)?

The CPT code for VAXNEUVANCE is 90671.

The information provided here is compiled from sources believed to be accurate, but Merck makes no representation that it is accurate. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of a particular code and for information on additional codes. This information is subject to change. Merck cautions that payer coding requirements vary and can frequently change, so it’s important to regularly check with each payer as to payer-specific requirements.

You are solely responsible for determining the appropriate codes and for any action you take in billing. The information provided here is not intended to be definitive or exhaustive, and is not intended to replace the guidance of a qualified professional advisor. Merck makes no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs. Diagnosis codes should be selected only by a health care professional.

Need CPT codes for other Merck vaccines?

Call the Merck Vaccine Reimbursement Support Center™ at 800.734.6282.

CPT, Current Procedural Terminology.
CPT is a registered trademark of the American Medical Association.

vaers

You are about to leave MerckVaccines.com

Vaccine Adverse Event Reporting System (VAERS)

Thank you for visiting.

Merck does not review or control the content at the site to which this link connects. Merck makes no representation with respect to the content of any non-Merck site.

Indication for VAXNEUVANCE

VAXNEUVANCE(Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older.

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.
Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

Do not administer VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

The most commonly reported solicited adverse reactions in individuals 18 through 49 years of age were: injection-site pain (75.8%), fatigue (34.3%), myalgia (28.8%), headache (26.5%), injection-site swelling (21.7%), injection-site erythema (15.1%), and arthralgia (12.7%).

The most commonly reported solicited adverse reactions in individuals 50 years of age and older were: injection-site pain (66.8%), myalgia (26.9%), fatigue (21.5%), headache (18.9%), injection-site swelling (15.4%), injection-site erythema (10.9%), and arthralgia (7.7%).

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

VAXNEUVANCE(Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older.

vaxRef

You are about to leave MerckVaccines.com

Vaxelis

Thank you for visiting.


US-PVC-00163 01/22